Stockreport

AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis

AIM ImmunoTech Inc.  (AIM) 
PDF OCALA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the United States Patent and Trad [Read more]